Jim Cramer on Eli Lilly: “It’s Become Luckless”

Group 1 - Eli Lilly and Company is under pressure to find new applications for its GLP-1 drug, Zepbound, or face a potential stock price decline to the $700s from its current $825 level [1] - The company is perceived to need a significant new drug indication that insurance companies will cover, as current offerings like Ozempic are seen as saturated [2] - There is a belief that while Eli Lilly has investment potential, certain AI stocks may offer better upside with less downside risk [2]